{
    "relation": [
        [
            "",
            "Cervarix Group",
            "Havrix Group"
        ],
        [
            "Description",
            "Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.",
            "Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm."
        ]
    ],
    "pageTitle": "Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00128661?sect=Xl3015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987174.71/warc/CC-MAIN-20150728002307-00137-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 858043283,
    "recordOffset": 858023037,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Solicited symptoms were collected for 3730 and 3740 subjects instead of the 3727 and 3739 subjects who were randomized in the study in the Cervarix and the Havrix groups, respectively. These 4 sujects received both vaccines and were included in the denominator of both arm based on the actual vaccine type administered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine Biological: hepatitis A inactivated virus vaccine Interventions: Cervical Cancer Precancerous Condition Conditions:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Cervarix Group \u00a0 \u00a0 Havrix Group \u00a0 STARTED \u00a0 \u00a0 3727 \u00a0 \u00a0 3739 \u00a0 COMPLETED \u00a0 \u00a0 3453 \u00a0 \u00a0 3481 \u00a0 NOT COMPLETED \u00a0 \u00a0 274 \u00a0 \u00a0 258 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 14 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 11 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 243 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}